Medicare Pricing Experiment Won't Extend To Part D, Senate Panel Told
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS Deputy Administrator Conway's appearance at the Finance Committee prompted questions about a theoretical next demonstration project while members challenged the project currently on the table; Conway suggested some ‘adjustments’ are coming to the proposed Part B demo.
You may also be interested in...
Trump, Congress And The Search For Common Ground On Drug Pricing
Trump’s ideas for curbing drug pricing have support in Congress but not among those in power; Republican leaders, including the president-elect’s choice for HHS secretary, Tom Price, have long opposed government negotiation in Medicare.
Part B Reference Pricing Faces 'Clinical' As Well As 'Political' Obstacles
Medicare pilot program on value-based purchasing could be challenged by a lack of therapeutic consensus as much as by opposition towards reduced reimbursement.
Have You Heard The Latest Rumor On Drug Pricing? Orrin Hatch Has
An exchange during HHS Secretary Burwell’s testimony to the Finance Committee on the fiscal 2017 budget speaks volumes about what is – and is not – on the table for the last year of the Obama Administration.